{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:01:16Z","timestamp":1778583676050,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"San Francisco Veterans Health System"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>\n                    <jats:italic toggle=\"yes\">Background<\/jats:italic>\n                    : Co-prescribing opioids and benzodiazepines increases overdose risk. A paucity of literature exists evaluating strategies to improve safety of co-prescribing. This study evaluated an electronic intervention to improve safety for patients co-prescribed chronic opioids for pain and benzodiazepines at 3 and 6\u00a0months.\n                    <jats:italic toggle=\"yes\">Methods<\/jats:italic>\n                    : A prospective cohort study was conducted from December 2015 through May 2016 at San Francisco Veterans Affairs Health Care System. A clinical dashboard identified 145 eligible patients prescribed chronic opioids and benzodiazepines. Individualized taper and safety recommendations were communicated to prescribers via electronic medical record progress note and encrypted e-mail at baseline. Primary outcome was number of patients co-prescribed chronic opioids and benzodiazepines. Secondary outcomes included daily dose of opioids and benzodiazepines and number prescribed \u2265100\u00a0mg morphine equivalent daily dose. Safety outcomes included number with opioid overdose education and naloxone distribution, annual urine drug screening, annual prescription drug monitoring program review, and signed opioid informed consent. Linear mixed models and generalized estimating equations were used to examine within-group change in outcomes between baseline and 3 and 6\u00a0months.\n                    <jats:italic toggle=\"yes\">Results<\/jats:italic>\n                    : Among the 145 patients, mean (standard deviation) age was 62 (11) years and 91.7% (133\/145) were male. Number co-prescribed significantly decreased from 145\/145 (100%) at baseline to 93\/139 (67%) at 6-month follow-up (odds ratio [OR] = 0.53, 95% confidence interval [CI]: 0.34\u20130.81,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .003). Mean opioid and benzodiazepine doses significantly decreased from 84.61 to 65.63\u00a0mg (95% CI: 8.32\u201327.86,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001) and from 16.10 to 13.45\u00a0mg (95% CI: 1.6\u20133.9,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001), respectively, from baseline to 6-month follow-up. Patients prescribed \u2265100\u00a0mg morphine equivalent daily dose significantly decreased from 39\/145 (26.8%) at baseline to 26\/139 (18.7%) at end of study (OR = 0.59, 95% CI: 0.44\u20130.78,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001), and patients with opioid overdose education and naloxone distribution significantly increased from 3\/145 (2.1%) at baseline to 46\/139 (33.1%; OR = 23.4, 95% CI: 7.61\u201371.99,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt; .001) by the end of study. Number of patients with annual urine drug screening tended to increase from 123\/145 (84.8%) at baseline to 132\/145 (91.4%) by the end of study (OR = 1.89, 95% CI: 0.95\u20133.76,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = .07), and there were no significant changes across time in numbers of patients with annual prescription drug monitoring program review or signed opioid informed consent.\n                    <jats:italic toggle=\"yes\">Conclusions<\/jats:italic>\n                    : Electronic interventions may provide an effective strategy to improve safety for patients co-prescribed chronic opioids for pain and benzodiazepines.\n                  <\/jats:p>","DOI":"10.1080\/08897077.2018.1455163","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T11:08:07Z","timestamp":1522321687000},"page":"441-448","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["An Electronic Intervention to Improve Safety for Pain Patients Co-Prescribed Chronic Opioids and Benzodiazepines"],"prefix":"10.1177","volume":"39","author":[{"given":"Tauheed","family":"Zaman","sequence":"first","affiliation":[{"name":"Addiction Recovery Treatment Services, Department of Mental Health, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA"},{"name":"Department of Psychiatry, University of California, San Francisco School of Medicine, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa L.","family":"Rife","sequence":"additional","affiliation":[{"name":"Addiction Recovery Treatment Services, Department of Mental Health, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA"},{"name":"Department of Pharmacy, University of California, San Francisco School of Pharmacy, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Batki","sequence":"additional","affiliation":[{"name":"Addiction Recovery Treatment Services, Department of Mental Health, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA"},{"name":"Department of Psychiatry, University of California, San Francisco School of Medicine, San Francisco, California, USA"},{"name":"Northern California Institute for Research and Education, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Pennington","sequence":"additional","affiliation":[{"name":"Addiction Recovery Treatment Services, Department of Mental Health, San Francisco Veterans Affairs Health Care System, San Francisco, California, USA"},{"name":"Department of Psychiatry, University of California, San Francisco School of Medicine, San Francisco, California, USA"},{"name":"Northern California Institute for Research and Education, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"National Institute on Drug Abuse. National overdose deaths: number of deaths from opioid drugs. 2017; Available at: https:\/\/www.drugabuse.gov\/related-topics\/trends-statistics\/overdose-death-rates. Accessed October 6 2017."},{"issue":"22","key":"e_1_3_3_3_2","first-page":"1","article-title":"Increase in fatal poisonings involving opioid analgesics in the United States, 1999\u20132006","author":"Warner M","year":"2009","unstructured":"Warner M, , Chen LH, , Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999\u20132006. NCHS Data Brief. 2009;(22):1\u20138. PMID:19796521.","journal-title":"NCHS Data Brief."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.272"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.07.004"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2016.303061"},{"key":"e_1_3_3_7_2","unstructured":"U.S. Food & Drug Administration (FDA) News Release. FDA requires strong warnings for opioid analgesics prescription opioid cough products and benzodiazepine labeling related to serious risks and death from combined use. 2016; Available at: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm518697.htm. Accessed October 6 2017."},{"key":"e_1_3_3_8_2","volume-title":"Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health","author":"US Department of Health and Human Services (HHS), Office of the Surgeon General","year":"2016","unstructured":"US Department of Health and Human Services (HHS), Office of the Surgeon General. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington, DC: HHS, November 2016"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12594"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000021"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S85667"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb09911.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2698"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12480"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.234"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.08.002"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3182490bdb"},{"key":"e_1_3_3_18_2","unstructured":"Department of Veterans Affairs Office of the Inspector General. Report No. 14\u201300895-163: healthcare Inspection\u2014VA patterns of dispensing take-home opioids and monitoring patients on opioid therapy. 2014; Available at: http:\/\/www.va.gov\/oig\/apps\/info\/OversightReports.aspx. Accessed October 6 2017."},{"key":"e_1_3_3_19_2","unstructured":"Department of Veterans Affairs Under Secretary for Health. Memorandum to network directors: opioid safety initiative requirements. April 2 2014."},{"key":"e_1_3_3_20_2","unstructured":"Department of Veterans Affairs Acting Deputy Under Secretary for Health for Operations and Management. Memorandum to VISN directors: opioid safety initiative updates. December 10 2014; Available at: https:\/\/www.va.gov\/vhapublications\/index.cfm."},{"key":"e_1_3_3_21_2","unstructured":"Department of Veterans Affairs Under Secretary for Health. Informational letter: implementation of opioid overdose education and naloxone distribution (OEND) to reduce risk of opioid-related death. May 13 2014."},{"key":"e_1_3_3_22_2","unstructured":"Department of Veterans Affairs Assistant Deputy Under Secretary for Health for Clinical Operations. Memorandum to network directors: opioid safety initiative progress report. July 2 2015."},{"key":"e_1_3_3_23_2","unstructured":"Department of Veterans Affairs Veterans Health Administration Directive 1005. Informed consent for long-term opioid therapy for pain. 2014; Available at: http:\/\/www.va.gov\/vhapublications\/publications.cfm?pub=1. Accessed October 6 2017."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"e_1_3_3_25_2","volume-title":"Psychotropic Drug Handbook","author":"Perry PJ","year":"2007","unstructured":"Perry PJ. Psychotropic Drug Handbook. Philadelphia, PA: Lippincott Williams & Wilkins; 2007."},{"key":"e_1_3_3_26_2","volume-title":"Drug Information Handbook for Psychiatry: Including Psychotropic, Non-Psychotropic, and Herbal Agents","author":"Fuller MA","year":"2009","unstructured":"Fuller MA, , Sajatovic M. Drug Information Handbook for Psychiatry: Including Psychotropic, Non-Psychotropic, and Herbal Agents. Hudson, Ohio: Lexi-Comp; 2009."},{"key":"e_1_3_3_27_2","volume-title":"IBM SPSS Statistics for Windows","author":"IBM","year":"2012","unstructured":"IBM. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp; 2012"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531734"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.2307\/2531248"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.10.008"},{"issue":"3","key":"e_1_3_3_31_2","first-page":"S67","article-title":"American Society of interventional pain physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2\u2014guidance","volume":"15","author":"Manchikanti L","year":"2012","unstructured":"Manchikanti L, , Abdi S, , Atluri S, . American Society of interventional pain physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2\u2014guidance. Pain Physician. 2012;15(3 Suppl):S67\u2013S116. PMID:22786449.","journal-title":"Pain Physician."},{"key":"e_1_3_3_32_2","volume-title":"VA\/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. Version 3.0","author":"The Opioid Therapy for Chronic Pain Work Group","year":"2017","unstructured":"The Opioid Therapy for Chronic Pain Work Group. VA\/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. Version 3.0. Washington, DC: Veterans Health Administration and Department of Defense, 2017"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2008.136937"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-010-9495-8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60928-4"},{"key":"e_1_3_3_36_2","first-page":"10","article-title":"CDC Grand Rounds: prescription drug overdoses\u2014a U.S. epidemic","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","unstructured":"Centers for Disease Control and Prevention. CDC Grand Rounds: prescription drug overdoses\u2014a U.S. epidemic. MMWR Morb Mort Wkly Rep. 2012;61:10\u201313.","journal-title":"MMWR Morb Mort Wkly Rep."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199909000-00005"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000080159.83342.B5"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2003\/6\/173"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1081\/JA-200030572"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200207001-00009"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31802b4f95"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.02.432"},{"key":"e_1_3_3_44_2","volume-title":"Justice UDto, ed.","author":"Simeone R","year":"2006","unstructured":"Simeone R, , Holland L. An Evaluation of Prescription Drug Monitoring. In: Justice UDto, ed. Washington, DC: Office of Justice Programs; 2006"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.4137\/SART.S2345"},{"key":"e_1_3_3_46_2","volume-title":"Institute of Pharmaceutical Outcomes and Policy DoPPaS, ed.","author":"Blumenschein K","year":"2010","unstructured":"Blumenschein K, , Fink JL, , Freeman PR, , Kirsh KL, , Steinke DT, , Talbert J. Independent evaluation of the impact and effectiveness of the kentucky all schedule prescription electronic reporting program (KASPER). In: Institute of Pharmaceutical Outcomes and Policy DoPPaS, ed. University of Kentucky, Lexington, Kentucky: College of Pharmacy; 2010"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2009.12.011"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00254.x"},{"issue":"12","key":"e_1_3_3_49_2","first-page":"621","article-title":"Effect of an opioid management system on opioid prescribing and unscheduled visits in a large primary care clinic","volume":"12","author":"Goldberg KC","year":"2005","unstructured":"Goldberg KC, , Simel DL, , Oddone EZ. Effect of an opioid management system on opioid prescribing and unscheduled visits in a large primary care clinic. JCOM. 2005;12(12):621\u2013628.","journal-title":"JCOM."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2006\/9\/57"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnv079"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.27.2.239"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2003.12.002"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.925444"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmi065"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1129526"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1081\/JA-200052433"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2018.1455163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2018.1455163","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2018.1455163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:50:09Z","timestamp":1777625409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2018.1455163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1080\/08897077.2018.1455163"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2018.1455163","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}